Endothelin receptor B controls the production of fibroblast growth factor 23.
ET-1
klotho
phosphate
vitamin D
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
12
12
2019
revised:
21
02
2020
accepted:
27
02
2020
pubmed:
12
3
2020
medline:
26
1
2021
entrez:
12
3
2020
Statut:
ppublish
Résumé
Endothelin-1 (ET-1) is a member of the endothelin family of peptide hormones first discovered as endothelium-derived mediators regulating vascular tone. ET-1 also regulates the proliferation and differentiation of bone cells that synthesize fibroblast growth factor 23 (FGF23). FGF23 is a hormone controlling renal phosphate and vitamin D metabolism. Here, we studied the role of ET-1 and endothelin receptor B (ETB) for FGF23 production. Fgf23 gene expression was studied in IDG-SW3 bone cells by quantitative RT-PCR. ETB-expressing (etb
Identifiants
pubmed: 32157737
doi: 10.1096/fj.201903109R
doi:
Substances chimiques
EDNRB protein, mouse
0
Fgf23 protein, mouse
0
Phosphates
0
Receptor, Endothelin B
0
Fibroblast Growth Factors
62031-54-3
Fibroblast Growth Factor-23
7Q7P4S7RRE
Calcium
SY7Q814VUP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6262-6270Informations de copyright
© 2020 Federation of American Societies for Experimental Biology.
Références
Kristianto J, Johnson MG, Afzal R, Blank RD. Endothelin Signaling in Bone. Endocrinol Metab Clin North Am. 2017;46:51-62.
Gohar EY, Kasztan M, Pollock DM. Interplay between renal endothelin and purinergic signaling systems. Am J Physiol Renal Physiol. 2017;313:F666-F668.
Fozard JR, Part ML. The role of nitric oxide in the regional vasodilator effects of endothelin-1 in the rat. Br J Pharmacol. 1992;105:744-750.
Böhm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res. 2007;76:8-18.
Kohan DE, Barton M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int. 2014;86:896-904.
Clouthier DE, Garcia E, Schilling TF. Regulation of facial morphogenesis by endothelin signaling: insights from mice and fish. Am J Med Genet A. 2010;152A:2962-2973.
Johnson MG, Kristianto J, Yuan B, Konicke K, Blank R. Big endothelin changes the cellular miRNA environment in TMOb osteoblasts and increases mineralization. Connect Tissue Res. 2014;55(Suppl 1):113-116.
Hu MC, Shi M, Moe OW. Role of αKlotho and FGF23 in regulation of type II Na-dependent phosphate co-transporters. Pflugers Arch. 2019;471:99-108.
Erben RG. Physiological actions of fibroblast growth factor-23. Front Endocrinol. 2018;9:267.
Leifheit-Nestler M, Haffner D. Paracrine effects of FGF23 on the heart. Front Endocrinol. 2018;9:278.
Faul C. Cardiac actions of fibroblast growth factor 23. Bone. 2017;100:69-79.
Erben RG, Andrukhova O. FGF23-Klotho signaling axis in the kidney. Bone. 2017;100:62-68.
Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007;117:4003-4008.
Andrukhova O, Smorodchenko A, Egerbacher M, et al. FGF23 promotes renal calcium reabsorption through the TRPV5 channel. EMBO J. 2014;33:229-246.
Fitzpatrick EA, Han X, Xiao Z, Quarles LD. Role of fibroblast growth factor-23 in innate immune responses. Front Endocrinol. 2018;9:320.
Singh S, Grabner A, Yanucil C, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 2016;90:985-996.
Faul C. FGF23 effects on the heart-levels, time, source, and context matter. Kidney Int. 2018;94:7-11.
Smith ER, Holt SG, Hewitson TD. αKlotho-FGF23 interactions and their role in kidney disease: a molecular insight. Cell Mol Life Sci. 2019;76(23):4705-4724.
Bär L, Stournaras C, Lang F, Föller M. Regulation of fibroblast growth factor 23 (FGF23) in health and disease. FEBS Lett. 2019;593:1879-1900.
Chen B, Huang S, Pisanic Ii TR, et al. Rab8 GTPase regulates Klotho-mediated inhibition of cell growth and progression by directly modulating its surface expression in human non-small cell lung cancer. EBioMedicine. 2019;49:118-132.
Wright JD, An S-W, Xie J, Lim C, Huang C-L. Soluble klotho regulates TRPC6 calcium signaling via lipid rafts, independent of the FGFR-FGF23 pathway. FASEB J. 2019;33:9182-9193.
Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393-4408.
Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113:561-568.
Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45-51.
Kuro-O M. Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol. 2013;9:650-660.
Kendrick J, Kestenbaum B, Chonchol M. Phosphate and cardiovascular disease. Adv Chronic Kidney Dis. 2011;18:113-119.
Kaludjerovic J, Komaba H, Sato T, et al. Klotho expression in long bones regulates FGF23 production during renal failure. FASEB J. 2017;31:2050-2064.
Isakova T, Cai X, Lee J, et al. Longitudinal FGF23 trajectories and mortality in patients with CKD. J Am Soc Nephrol. 2018;29:579-590.
Jovanovich A, You Z, Isakova T, et al. Fibroblast growth factor 23 trajectories in chronic hemodialysis patients: lessons from the HEMO study. Am J Nephrol. 2019;49:263-270.
Spichtig D, Zhang H, Mohebbi N, et al. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. Kidney Int. 2014;85:1340-1350.
Emma F, Haffner D. FGF23 blockade coming to clinical practice. Kidney Int. 2018;94:846-848.
Stöhr R, Schuh A, Heine GH, Brandenburg V. FGF23 in cardiovascular disease: innocent bystander or active mediator? Front Endocrinol. 2018;9:351.
Schnedl C, Fahrleitner-Pammer A, Pietschmann P, Amrein K. FGF23 in acute and chronic illness. Dis Markers. 2015;2015:358086.
Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370-1378.
Agoro R, Montagna A, Goetz R, et al. Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia. FASEB J. 2018;32:3752-3764.
Masuyama R, Stockmans I, Torrekens S, et al. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest. 2006;116:3150-3159.
Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010;299:F882-F889.
Francis C, David V. Inflammation regulates fibroblast growth factor 23 production. Curr Opin Nephrol Hypertens. 2016;25:325-332.
Chonchol M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK. Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study. J Am Soc Nephrol. 2016;27:227-237.
Durlacher-Betzer K, Hassan A, Levi R, Axelrod J, Silver J, Naveh-Many T. Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease. Kidney Int. 2018;94:315-325.
David V, Martin A, Isakova T, et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 2016;89:135-146.
Daryadel A, Bettoni C, Haider T, et al. Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men. Pflugers Archiv. 2018;470:1569-1582.
Daryadel A, Natale L, Seebeck P, et al. Elevated FGF23 and disordered renal mineral handling with reduced bone mineralization in chronically erythropoietin over-expressing transgenic mice. Sci Rep. 2019;9:14989.
Hanudel MR, Eisenga MF, Rappaport M, et al. Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. Nephrol Dial Transplant. 2019;34:2057-2065.
Tagliabracci VS, Engel JL, Wiley SE, et al. Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci U S A. 2014;111:5520-5525.
Glosse P, Feger M, Mutig K, et al. AMP-activated kinase is a regulator of fibroblast growth factor 23 production. Kidney Int. 2018;94:491-501.
Bär L, Feger M, Fajol A, et al. Insulin suppresses the production of fibroblast growth factor 23 (FGF23). Proc Natl Acad Sci U S A. 2018;115:5804-5809.
Semler DE, Ohlstein EH, Nambi P, Slater C, Stern PH. Endothelin-1-evoked calcium transients in UMR-106 osteoblastic osteosarcoma cells are mediated through endothelin-A and endothelin-B receptors. J Pharmacol Exp Ther. 1995;272:1052-1058.
Quaschning T, Rebhan B, Wunderlich C, et al. Endothelin B receptor-deficient mice develop endothelial dysfunction independently of salt loading. J Hypertens. 2005;23:979-985.
Smith ER, Cai MM, McMahon LP, Holt SG. Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab. 2012;97:3357-3365.
Correale M, Ferraretti A, Monaco I, Grazioli D, Di Biase M, Brunetti ND. Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand? Vasc Health Risk Manag. 2018;14:253-264.
Kandalaft LE, Facciabene A, Buckanovich RJ, Coukos G. Endothelin B receptor, a new target in cancer immune therapy. Clin Cancer Res. 2009;15:4521-4528.
Sin A, Tang W, Wen CY, Chung SK, Chiu KY. The emerging role of endothelin-1 in the pathogenesis of subchondral bone disturbance and osteoarthritis. Osteoarthritis Cartilage. 2015;23:516-524.
Heerspink HJL, Parving H-H, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019;393:1937-1947.